HomeCompareSSMXY vs JNJ

SSMXY vs JNJ: Dividend Comparison 2026

SSMXY yields 1.20% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $5.1K in total portfolio value· pulled ahead in Year 8
10 years
SSMXY
SSMXY
● Live price
1.20%
Share price
$8.69
Annual div
$0.10
5Y div CAGR
20.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$975.85
Full SSMXY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SSMXY vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSSMXYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SSMXY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SSMXY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SSMXY
Annual income on $10K today (after 15% tax)
$102.07/yr
After 10yr DRIP, annual income (after tax)
$829.47/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,156.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SSMXY + JNJ for your $10,000?

SSMXY: 50%JNJ: 50%
100% JNJ50/50100% SSMXY
Portfolio after 10yr
$27.7K
Annual income
$2,832.63/yr
Blended yield
10.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SSMXY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
5.0
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SSMXY buys
0
JNJ buys
0
No recent congressional trades found for SSMXY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSSMXYJNJ
Forward yield1.20%2.13%
Annual dividend / share$0.10$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR20.8%28%
Portfolio after 10y$25.1K$30.3K
Annual income after 10y$975.85$4,689.40
Total dividends collected$4.4K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: SSMXY vs JNJ ($10,000, DRIP)

YearSSMXY PortfolioSSMXY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,845$145.06$10,592$272.30+$253.00SSMXY
2$11,782$177.60$11,289$357.73+$493.00SSMXY
3$12,824$217.83$12,123$472.89+$701.00SSMXY
4$13,990$267.69$13,141$629.86+$849.00SSMXY
5$15,299$329.67$14,408$846.81+$891.00SSMXY
6$16,777$407.02$16,021$1,151.60+$756.00SSMXY
7$18,455$503.90$18,122$1,588.22+$333.00SSMXY
8← crossover$20,373$625.80$20,930$2,228.20$557.00JNJ
9$22,579$779.92$24,792$3,191.91$2.2KJNJ
10$25,135$975.85$30,274$4,689.40$5.1KJNJ

SSMXY vs JNJ: Complete Analysis 2026

SSMXYStock

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Full SSMXY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SSMXY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SSMXY vs SCHDSSMXY vs JEPISSMXY vs OSSMXY vs KOSSMXY vs MAINSSMXY vs ABBVSSMXY vs MRKSSMXY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.